StreetInsider.com News Articles

Form 8-K Skye Bioscience, Inc. For: May 26

Fri, 29 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260529/26576182.html

Form 8-K Skye Bioscience, Inc. For: May 26

Fri, 29 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260529/26576182.html

Skye Bioscience clears nimacimab dose escalation in obesity trial

Wed, 20 May 2026 07:02:21 -0400

Skye Bioscience Inc. (NASDAQ: SKYE) announced that its Cohort Review Committee approved the opening of Cohort 2 in the CBeyond Part C Expansion Study based on safety data from the first four participants in Cohort 1.

The committee approved enrollment in Cohort 2, which will test nimacimab at 600 mg IV weekly, after reviewing safety data from participants who completed four weeks of treatment in Cohort 1 at 400 mg IV weekly. The 400 mg dose represents the highest level previously tested for nimacimab.

The expansion study includes two cohorts testing nimacimab monotherapy at 400 mg IV and 600 mg IV compared

Skye Bioscience clears nimacimab dose escalation in obesity trial

Wed, 20 May 2026 07:02:21 -0400

The expansion study includes two cohorts testing nimacimab monotherapy at 400 mg IV and 600 mg IV compared

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Wed, 20 May 2026 07:00:00 -0400

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee (CRC) responsible for reviewing safety data generated from the CBeyond Part C Expansion Study, and for approving the opening of enrollment in Cohort 2 has unanimously approved opening the second cohort of the CBeyond Part C Expansion study. The CRC focuses exclusively on the safety of the Part C Expansion Study and does not conduct efficacy assessments. The independent Data Monitoring

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Wed, 20 May 2026 07:00:00 -0400

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Wed, 20 May 2026 07:00:00 -0400

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Wed, 20 May 2026 07:00:00 -0400

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Wed, 20 May 2026 07:00:00 -0400

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Wed, 20 May 2026 07:00:00 -0400

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Wed, 20 May 2026 07:00:00 -0400

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Wed, 20 May 2026 07:00:00 -0400

Form 8-K Skye Bioscience, Inc. For: May 13

Fri, 15 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26504607.html

Form 8-K Skye Bioscience, Inc. For: May 13

Fri, 15 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26504607.html

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Tue, 12 May 2026 13:33:00 -0400

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.